Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda or Keytruda Qlex + Padcev
pembrolizumab (IV or with berahyaluronidase alfa-pmph SC) + enfortumab vedotin-ejfv · Merck and Astellas Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With either pembrolizumab formulation and enfortumab vedotin-ejfv before cystectomy and as adjuvant therapy afterward for adults with muscle-invasive bladder cancer who are ineligible for cisplatin.
LAMPGEN ANALYSIS
Why it matters
This decision added a perioperative checkpoint inhibitor and antibody–drug conjugate regimen for cisplatin-ineligible patients.
What research teams should watch
Capture the basis for cisplatin ineligibility, protect the surgery window, and assign responsibility for rash and neuropathy monitoring.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Perioperative muscle-invasive bladder cancerPRIMARY RECORDS